MIST - Milestone Pharmaceuticals: Interesting But Not Well-Differentiated From Generic Competition
Very few drugs are available for the cardiovascular sector, and even fewer companies actually develop a specialty focus in this area. Milestone Pharmaceuticals (MIST) is one of them. The company has a pipeline focusing on CV diseases, and its lead candidate etripamil is in late stage trial targeting paroxysmal supraventricular tachycardia.
The disease and the science
Paroxysmal supraventricular tachycardia or PSVT is a type of supraventricular tachycardia. That means, electric pulses in the heart’s upper chambers do not work properly, and the heart beats too fast to properly fill in blood. People may